Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Diabetes Publish Ahead of Print published online ahead of print January 30, 2008
DOI: 10.2337/db07-1238
This Article
Right arrow Full Text (PDF)
Right arrow Online-Only Appendix
Right arrow Online-Only Appendix
Right arrow All Versions of this Article:
db07-1238v1
db07-1238v2
57/4/809    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lai, C.-Q.
Right arrow Articles by Ordovás, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lai, C.-Q.
Right arrow Articles by Ordovás, J. M.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

PPARGC1A (PGC-1{alpha}) variation associated with DNA damage, diabetes and cardiovascular diseases: the Boston Puerto Rican Health Study

Chao-Qiang Lai1, Katherine L. Tucker2, Laurence D. Parnell1, Xian Adiconis1, Bibiana García-Bailo1, John Griffith3, Mohsen Meydani4, and José M. Ordovás1

1Nutrition and Genomics Laboratory
2Dietary Assessment and Epidemiology Research; Program
3Biostatistics Research Center at Tufts New England Medical Center
4Vascular Biology Laboratory JM-USDA Human Nutrition Research Center on Aging at Tufts University, Boston MA

Objective: Individuals with type 2 diabetes exhibit higher DNA damage and increased risk of cardiovascular disease (CVD). However, mechanisms underlying the association between DNA damage and development of type 2 diabetes and CVD are not understood. We sought to link peroxisome proliferator-activated receptor-{gamma} coactivator-1 alpha (PPARGC1A), a master transcriptional regulator of mitochondrial oxidative phosphorylation and cellular energy metabolism, with DNA damage, type 2 diabetes and CVD.

Research Design and Methods: We measured DNA damage as urinary 8-hydroxydeoxyguanosine (8-OHdG) concentration and examined the relationship between nine PPARGC1A genetic variants, DNA damage, type 2 diabetes, and self-reported CVD in 959 participants of the Boston Puerto Rican Health Study.

Results: With respect to urinary 8-OHdG, PPARGC1A variants showed significant association, whereas PPARGC1A haplotypes exhibited significant association after correction for multiple testing. Two independent PPARGC1A variants associated significantly with type 2 diabetes (OR=1.35 and 2.46, P=0.045 and <0.001). Carriers of minor alleles of two other PPARGC1A variants, both in strong LD and associated with lower DNA damage, showed lower prevalence of CVD (OR=0.53 and 0.65, P=0.030 and 0.175). Moreover, we found that physical activity correlated negatively with DNA damage.

Conclusions: Low physical activity combined with risk haplotyes plausibly forms the basis for the high prevalence of type 2 diabetes in this population. We propose that PPARGC1A influences development of type 2 diabetes and CVD via DNA damage. Increasing physical activity, which induces PPARGC1A expression, is a potential strategy to slow DNA damage, thereby decreasing the risk of CVD for individuals with type 2 diabetes.

Correspondence: chaoqiang.lai{at}ars.usda.gov


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.